Dongsheng Yue

Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial

Dongsheng Yue, Shidong Xu, Qun Wang et al. · The Lancet Respiratory Medicine · 2018 · 288 citations

Medicine, Pathology, Erlotinib Versus Vinorelbine +8

Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer

Xiaoyan Sun, Weiran Liu, Leina Sun et al. · Journal for ImmunoTherapy of Cancer · 2022 · 123 citations · Full text

Circulating tumor DNA predicts neoadjuvant immunotherapy efficacy and recurrence-free survival in surgical non-small cell lung cancer patients

Dongsheng Yue, Weiran Liu, Chen Chen et al. · Translational Lung Cancer Research · 2022 · 100 citations · Full text

LncRNA H19 downregulation confers erlotinib resistance through upregulation of PKM2 and phosphorylation of AKT in EGFR-mutant lung cancers

Chen Chen, Wei-Ran Liu, Bin Zhang et al. · Cancer Letters · 2020 · 96 citations

Medicine, Cancer Cell Biology, Cancer Biology +7

Hedgehog/Gli promotes epithelial-mesenchymal transition in lung squamous cell carcinomas

Dongsheng Yue, Hui Li, Juanjuan Che et al. · Journal of Experimental & Clinical Cancer Research · 2014 · 94 citations · Full text